LivaNova (LIVN) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
1 Feb, 2026Opening remarks and agenda
The meeting was conducted virtually to maximize shareholder participation globally, with instructions for submitting questions provided at the outset.
Notice of the meeting and agenda were distributed to all entitled parties, and quorum requirements were confirmed.
Board and executive committee updates
Board members and key executives, including the CEO, CFO, and other officers, were introduced at the start of the meeting.
Special recognition was given to Dan Moore for his service as Chair and his contributions to the Board and governance committee.
Overview of voting outcomes
Over 48 million shares, representing approximately 89% of voting rights, were present or voted at the meeting.
Voting covered 12 resolutions, including director elections, executive compensation, auditor appointments, and incentive plan amendments.
Final voting results will be published on the company website and filed with the SEC.
Latest events from LivaNova
- Raised 2026 revenue and EPS guidance after double-digit Q1 growth and key regulatory wins.LIVN
Q1 20266 May 2026 - Shareholders will vote on directors, executive pay, auditors, share authority, and ESG initiatives.LIVN
Proxy filing29 Apr 2026 - AGM to address director elections, compensation, auditor matters, and share capital authorities.LIVN
Proxy filing29 Apr 2026 - Double-digit 2025 growth and margin gains set stage for 6–7% revenue growth in 2026.LIVN
Q4 202525 Feb 2026 - Q2 revenue up 10% and adjusted EPS up, with raised 2024 guidance and strong segment growth.LIVN
Q2 20242 Feb 2026 - Core growth, innovation in DTD/OSA, and margin expansion drive a multi-year growth outlook.LIVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Sustained growth driven by talent, innovation, and strategic execution, with a 2030 vision.LIVN
Baird 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 11.2%, margins expand, and guidance raised on strong segment growth.LIVN
Q3 202417 Jan 2026 - OSA market entry and reimbursement gains drive growth, with profitability targeted by 2029.LIVN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026